

**PFIC ANNUAL INFORMATION STATEMENT
 ESSA PHARMA INC.**

This Information Statement is for the taxable year of ESSA Pharma Inc. (“ESSA” or the “Company”) beginning on October 1, 2017 and ending on September 30, 2018 (the “Taxable Year”) and is provided for the convenience of any U.S. shareholder who held shares in ESSA when ESSA was a passive foreign investment company (“PFIC”) and had a QEF election in effect, in connection with their preparation of U.S. Internal Revenue Service Form 8621.

For the Taxable Year (as defined above), the Company:

was a PFIC
 was not a PFIC (skip earning and distribution sections).

Investor’s pro-rata share of the Company’s ordinary earnings and net capital gain (as determined under U.S. federal income tax principles) for the Taxable Year follows:

Ordinary Earnings ¹	\$nil
Net Capital Gains	\$nil

This information is provided to enable you to calculate your pro rata shares of ESSA’s ordinary earnings and net capital gain for the Taxable Year.

The amount of cash and fair market value of other property distributed or deemed distributed by the Corporation to Investor during the Taxable Year was:

Cash	\$nil
Fair Market Value of Property	\$nil

This information is provided to enable you to calculate your pro rata amounts of cash and fair market value of other property distributed or deemed distributed by ESSA during the Taxable Year.

In accordance with Treasury Regulation Section 1.1295-1(g)(1)(iv), ESSA will permit the shareholder to examine its permanent books of account, records and such other documents as may be maintained by ESSA that are necessary to establish that PFIC ordinary earnings and net capital gain, as provided in section 1293(e) of the Internal Revenue Code, are computed in accordance with U.S. income tax principles and to verify these amounts and the shareholder’s pro rata shares thereof.

THIS INFORMATION IS PROVIDED IN ORDER TO ASSIST SHAREHOLDERS IN MAKING CALCULATIONS AND DOES NOT CONSTITUTE TAX ADVICE. SHAREHOLDERS ARE URGED TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE OVERALL TAX CONSEQUENCES OF THE OWNERSHIP OF ESSA SHARES ARISING IN THEIR OWN PARTICULAR SITUATIONS UNDER UNITED STATES FEDERAL, STATE, LOCAL, OR FOREIGN LAW.

ESSA Pharma Inc.

By: /s/ “David Wood” David Wood, Chief Financial Officer December 18, 2018

¹ The term “ordinary earnings” means the excess of the earnings and profits of the PFIC for the taxable year over its net capital gain for the same taxable year.